|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA; Department ofPhysiology, Medical College of Georgia, Atlanta, Georgia, USA
2 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia, USA
3 Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia, USA
4 Department ofPhysiology, Medical College of Georgia, Atlanta, Georgia, USA
5 Department of Physiology, Emory University School of Medicine, Atlanta, Georgia, USA
6 Dean of the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
* To whom correspondence should be addressed. E-mail: mmarrero{at}mcg.edu.
In the current study, we investigated the effect of simvastatin on the ability of high glucose (HG) and angiotensin II (Ang II) to activate the JAK2-STAT signaling cascade and induce glomerular mesangial cell (GMC) growth. We found that pretreatment with simvastatin significantly inhibited HG- and Ang II-induced collagen IV production, JAK2 activation and phosphorylation of STAT1 and STAT3 in GMC. We also found that the activation of JAK2 by HG and AngII was dependent on the Rho family of GTPases. Consistent with these in vitro results, both albumin protein excretion and phosphorylation of JAK2, STAT1 and STAT3 were attenuated in renal glomeruli by administration of simvastatin in a streptozotocin-induced rat model of HG diabetes. This study demonstrates that simvastatin blocks Ang II-induced activation of the JAK/STAT pathway in the diabetic environment, in vitro and in vivo, and, thereby, provides new insights into the molecular mechanisms underlying early diabetic nephropathy.
This article has been cited by other articles:
![]() |
M. Ruperez, R. Rodrigues-Diez, L. M. Blanco-Colio, E. Sanchez-Lopez, J. Rodriguez-Vita, V. Esteban, G. Carvajal, J. J. Plaza, J. Egido, and M. Ruiz-Ortega HMG-CoA Reductase Inhibitors Decrease Angiotensin II-Induced Vascular Fibrosis: Role of RhoA/ROCK and MAPK Pathways Hypertension, August 1, 2007; 50(2): 377 - 383. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |